NCT07010432 - The Role of the Amylin Analogue Cagrilintide in Bone Metabolism | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

May 3, 2028

Study Completion Date

May 3, 2028

Conditions

Obesity

Interventions

DRUG

Cagrilintide

Participants will receive once-weekly cagrilintide subcutaneously.

DRUG

Semaglutide

Participants will receive once-weekly semaglutide subcutaneously.

DRUG

Placebo cagrilintide

Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.

DRUG

Placebo semaglutide

Participants will receive once-weekly placebo matched to semaglutide subcutaneously.

Trial Locations (1)

RECRUITING

Steno Diabetes Center Copenhagen, Herlev